Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Endocrinology

• Publication date

  1990-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/ENDO-127-6-3052PMID 2174343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

  2009cited by this paper
• Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

  1991cited by this paper
• Evaluation of receptors for somatostatin in various tumors using different analogs.

  1990cited by this paper
• Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.

  1990cited by this paper
• Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.

  1990cited by this paper
• Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.

  1990cited by this paper
• Mapping of gonadotropin-releasing hormone-receptor binding site using selective chemical modifications.

  1989cited by this paper
• Receptors for d-Trp6-Luteinizing Hormone-Releasing Hormone, Somatostatin, and Insulin-Like Growth Factor I in MXT Mouse Mammary Carcinoma

  1989cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Receptors for luteinizing hormone‐releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia

  1989cited by this paper
• Autoradiographic Study of Binding and Internalization of a Luteinizing Hormone‐Releasing Hormone Antagonist [D‐Nal1, D‐Cpa2, A‐D‐Trp3, D‐Arg6, D‐Ala10]LHRH by Rat Pituitary Gonadotrophs

  1989cited by this paper
• Gonadotrophin-releasing hormone: its actions and receptors.

  1989cited by this paper
• Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes.

  1989cited by this paper
• Differential sensitivity of agonist- and antagonist-occupied gonadotropin-releasing hormone receptors to protein kinase C activators. A marker for receptor activation.

  1988cited by this paper
• Molecular mechanism of gonadotropin releasing hormone (GnRH) action. I. The GnRH receptor.

  1988cited by this paper
• Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.

  1988cited by this paper
• Use of Luteinizing Hormone - Releasing Hormone Analogs in the Treatment of Hormone-Dependent Tumors

  1987cited by this paper
• Pulsatile GnRH administration stimulates the number of pituitary GnRH receptors in seasonally anoestrous ewes.

  1987cited by this paper
• The molecular mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary.

  1987cited by this paper
• Phase II trial with D‐Trp‐6‐LH‐RH in prostatic carcinoma: Comparison with other hormonal agents

  1986cited by this paper
• High incidence of somatostatin receptors in human meningiomas: biochemical characterization.

  1986cited by this paper
• Gonadotrophin-releasing hormone (GnRH) overcomes GnRH antagonist-induced suppression of LH secretion in primates.

  1986cited by this paper
• Radiation inactivation (target size analysis) of the gonadotropin-releasing hormone receptor: evidence for a high molecular weight complex.

  1985cited by this paper
• Treatment of advanced prostatic carcinoma with D‐trp‐6‐LH‐RH

  1985cited by this paper
• Photoaffinity labeling of pituitary and gonadal receptors for gonadotropin-releasing hormone.

  1985cited by this paper
• Receptor-binding properties of gonadotropin-releasing hormone derivatives. Prolonged receptor occupancy and cell-surface localization of a potent antagonist analog.

  1984cited by this paper
• Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.

  1983cited by this paper
• Gonadotropin-releasing hormone binding to rat anterior pituitary membrane homogenates. Comparison of antagonists and agonists using radiolabeled antagonist and agonist.

  1983cited by this paper
• The presence of LHRH‐like receptors in Dunning R3327H prostate tumors

  1983cited by this paper
• Agonist-induced regulation of pituitary receptors for gonadotropin-releasing hormone. Dissociation of receptor recruitment from hormone release in cultured gonadotrophs.

  1983cited by this paper
• Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms.

  1983cited by this paper
• Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

  1982cited by this paper
• Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action.

  1982cited by this paper
• Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells.

  1982cited by this paper
• Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function.

  1981cited by this paper
• Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes.

  1981cited by this paper
• Effect of a potent GnRH antagonist and testosterone propionate on mating behavior and fertility in the male rat.

  1981cited by this paper
• LH‐RH Agonists and Antagonists

  1980cited by this paper
• Ligand: a versatile computerized approach for characterization of ligand-binding systems.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Relugolix in treatment of prostate cancer: a review.

  2025cites this paper
• Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer

  2021cites this paper
• Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions

  2020cites this paper
• Therapeutic outcomes of the LHRH antagonists

  2017cites this paper
• Reversible downregulation of the hypothalamic-pituitary-gonadal axis in stallions with a novel GnRH antagonist.

  2016cites this paper
• REVERSIBLE DOWNREGULATION OF HYPOTHALAMIC-PITUITARY-GONADAL AXIS IN THE STALLION WITH A THIRD-GENERATION GNRH ANTAGONIST

  2015cites this paper
• Synthesis and in vitro anti-cancer evaluation of luteinizing hormone-releasing hormone-conjugated peptide

  2015cites this paper
• Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies.

  2013cites this paper
• Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer

  2011cites this paper
• Hecate-CGbeta conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-alpha promoter.

  2009cites this paper
• Targeted ablation of gonadotropin dependent endocrine tumors in transgenic mice through their luteinizing hormone receptor (LHR)

  2009cites this paper
• Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.

  2009cites this paper
• GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas.

  2009cites this paper
• Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).

  2009cites this paper
• Comparative response of rams and bulls to long-term treatment with gonadotropin-releasing hormone analogs.

  2007cites this paper
• The mammalian type II gonadotropin-releasing hormone receptor : cloning, distribution and role in gonadotropin gene expression

  2006cites this paper
• Autocrine-inhibitory LHRH Loop Prostate Cancer Cell Line DU 145: Evidence for an Hormone (LHRH) Agonists on Human Androgen-independent Antiproliferative Effects of Luteinizing Hormone-releasing

  2006cites this paper
• Autocrine-inhibitory LHRH Loop Prostate Cancer Cell Line DU 145 : Evidence for an Hormone ( LHRH ) Agonists on Human Androgen-independent Antiproliferative Effects of Luteinizing Hormone-releasing

  2006cites this paper
• Effect of Leuprolide and Cetrorelix on Cell Growth, Apoptosis, and GnRH Receptor Expression in Primary Cell Cultures from Human Prostate Carcinoma

  2006cites this paper
• AÇÃO REGULATÓRIA DO GnRH NO DESENVOLVIMENTO EMBRIONÁRIO PRECOCE E VITRIFICAÇÃO DE EMBRIÕES SUÍNOS PELO MÉTODO DE MICROGOTA (ROLE OF GnRH DURING EARLY EMBRYONIC DEVELOPMENT AND DEVELOPMENT OF SWINE EMBRYOS FOLLOWING VITRIFICATION BY MICRODROPLET METHOD)

  2005cites this paper
• Regulation of Expression of Mammalian Gonadotrophin‐Releasing Hormone Receptor Genes

  2005cites this paper
• Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma.

  2005cites this paper
• Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy.

  2004cites this paper
• The effect of active immunization against gonadotropin-releasing hormone on the ultrastructure of the rat ventral prostate

  2004cites this paper
• The clinical implications of the difference between castration, gonadotrophin releasing‐hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate

  2003cites this paper
• Immunization Against Luteinizing Hormone-Releasing Hormone Fusion Proteins Does Not Decrease Prostate Cancer in the Transgenic Adenocarcinoma Mouse Prostate Model

  2003cites this paper
• Effect of GnRH conjugated to pokeweed antiviral protein on reproductive function in adult male dogs.

  2003cites this paper
• Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors

  2003cites this paper
• Recent developments in the hormonal treatment of breast cancer.

  2002cites this paper
• Gonadotropin-releasing hormone receptors in prostate tissue.

  2002cites this paper
• Gonadotropin‐releasing hormone receptor expression in the human prostate

  2001cites this paper
• Gonadotropin-releasing hormone antagonist: how good is the new hope?

  2001cites this paper
• Targeted destruction of androgen‐sensitive and ‐insensitive prostate cancer cells and xenografts through luteinizing hormone receptors

  2001cites this paper
• Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists.

  2000cites this paper
• Cytotoxic activity of a recombinant GnRH‐PAP fusion toxin on human tumor cell lines

  2000cites this paper
• High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.

  2000cites this paper
• the PHSCN Sequence in Prostate Carcinoma Anti-invasive , Antitumorigenic , and Antimetastatic Activities of Updated Version

  2000cites this paper
• Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles

  1999cites this paper
• Luteinizing hormone releasing hormone increases proliferation of meningioma cells in vitro.

  1999cites this paper
• Expression of gonadotropin‐releasing hormone receptor mRNA in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration

  1999cites this paper
• Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.

  1999cites this paper
• Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.

  1998cites this paper
• Induction of early and bioeffective antibody response in rodents with the luteinizing hormone‐releasing hormone vaccine given as a single dose in biodegradable microspheres along with alum

  1998cites this paper
• Effects of a GnRH analogue on human smooth muscle cells cultured from normal myometrial and from uterine leiomyomal tissues.

  1997cites this paper
• Effect of active immunization against luteinizing hormone‐releasing hormone on the androgen‐sensitive Dunning R3327‐PAP and androgen‐independent Dunning R3327‐AT2.1 prostate cancer sublines

  1997cites this paper
• Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin.

  1997cites this paper
• Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone.

  1996cites this paper
• Negative feedback on luteinizing hormone secretion requires infrequent exposure to testicular androgens

  1996cites this paper
• Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.

  1996cites this paper
• Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.

  1996cites this paper
• Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview.

  1995cites this paper
• Terminology for luteinizing hormone-releasing hormone antagonists.

  1995cites this paper
• Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin beta-subunit genes in normal and castrated rat pituitary.

  1995cites this paper
• Synthesis of [U‐14C]Arg labelled decapeptide cetrorelix, a novel lutenizing hormone — releasing hormone antagonist

  1994cites this paper
• High-performance liquid chromatographic assay for the determination of the decapeptide cetrorelix, a novel luteinizing hormone-releasing hormone antagonist, in human plasma.

  1994cites this paper
• Inhibition of luteal steroidogenesis by two LHRH antagonists (Nal-Glu and Nal-Arg antagonists) in the pregnant rat.

  1994cites this paper
• Luteinizing hormone has a role in development of fully functional corpora lutea (CL) but is not required to maintain CL function in heifers.

  1994cites this paper
• Suppression of luteal steroidogenesis by an LHRH antagonist (Nal-Lys antagonist: antide) in vitro during early pregnancy in the rat.

  1994cites this paper
• The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.

  1994cites this paper
• Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.

  1994cites this paper
• Antagonists of bombesin/gastrin‐releasing peptide as adjuncts to agonists of luteinizing hormone–releasing hormone in the treatment of experimental prostate cancer

  1993cites this paper
• Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.

  1993cites this paper
• Inhibition of growth of experimental prostate cancer in rats by LH‐RH analogs linked to cytotoxic radicals

  1993cites this paper
• Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system.

  1993cites this paper
• Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.

  1992cites this paper
• Effect of microcapsules of luteinizing hormone‐releasing hormone antagonist SB‐75 and somatostatin analog RC‐160 on endocrine status and tumor growth in the dunning R‐3327H rat prostate cancer model

  1992cites this paper
• Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160

  1992cites this paper
• Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.

  1992cites this paper
• LH-RH antagonists: state of the art and future perspectives.

  1992cites this paper
• Evaluation of luteinizing hormone-releasing hormone antagonistic activity in vitro.

  1992cites this paper
• Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor

  1992cites this paper
• Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats.

  1992cites this paper
• Arguments against the prostatic origin of the R-3327 Dunning H tumor

  1992cites this paper
• Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.

  1992cites this paper
• Blockade of the LH response induced by the agonist D‐Trp‐6‐LHRH in rats by a highly potent LH‐RH antagonist SB‐75

  1992cites this paper
• Histological changes in dunning prostate tumors and testes of rats treated with LH‐RH antagonist SB‐75

  1991cites this paper
• Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

  1991cites this paper
• Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).

  1991cites this paper